All Studies/Projects

Epidemiologic Factors Associated with TB Treatment Outcomes Across Report International Consortia

Post Date: 
2021-08-12
   |   
Rationale: RePORT International was designed to enable cross-consortium data analysis. Now that a large number of consortium sites have completed participant enrollment in Common Protocol Cohort A, we can proceed with large-scale analysis of aligned RePORT data. The current study will harmonize and...

ACTIV-2/A5401: Adaptive Platform Treatment for Outpatients with COVID-19 (Adapt Out COVID)

Post Date: 
2021-07-21
   |   
Countries: 
   |   
Clinical Sites: 
Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease progression, and reduce serious complications of COVID-19 and transmission [10]. ACTIV-2/A5401 is a phase II/III randomized, blinded, controlled adaptive platform trial to...

Project COVID-19 Test At Home

Post Date: 
2021-06-28
   |   
Countries: 
This study to test the accuracy of a COVID-19 test for use at home. This test has been authorized by the FDA to be done in a health care setting by a health care provider, but the study is evaluating diagnostic accuracy of tests administered at home

P2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs during Pregnancy and Postpartum

Post Date: 
2021-05-18
   |      |   
Clinical Sites: 
IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women, studied the PK of more than 25 HIV and TB drugs in these women and published 27 manuscripts presenting these data. P1026s data was cited in 32% of the 76 perinatal...

The Pharmacokinetics, Safety and Acceptability of New Child-Friendly Formulations of Clofazimine and Moxifloxacin in Children Routinely Treated for Rifampicin-Resistant Tuberculosis (CATALYST)

Post Date: 
2021-04-26
   |      |   
Clinical Sites: 
PK, safety and acceptability data and practical guidance on the optimal dosing of new more child-friendly formulations of moxifloxacin and clofazimine in children are urgently needed to inform their current and future use in children with Rifampicin-Resistant TB (RR-TB). Both medications have a key...

Dynamics and immune mechanisms of QFT response in close contacts of TB cases

Post Date: 
2021-04-05
   |   
Countries: 
   |   
Clinical Sites: 
Rationale: A vaccine that prevents infection with Mycobacterium tuberculosis (Mtb) (POI vaccine) is an ideal approach to TB control. As Mtb infection (MTBI) is measured indirectly (positive tuberculin skin test (TST) or interferon gamma release assay (IGRA), prevention of IGRA conversion is the...

A Nanopore Biosensor for Leveling MTB Antigens in Blood

Post Date: 
2021-04-01
   |   
Countries: 
   |   
Clinical Sites: 
Purpose of the study: The inability to obtain diagnostically useful sputum specimens, or the inability to analyze non-sputum specimens, is a significant contributor to poor diagnostic sensitivity of current TB assays, leading to the WHO to call for the development of non-sputum-based biomarker or...

Effect of Neighborhoods and Peer Networks on substance use and violence among adolescents living with and without HIV in India

Post Date: 
2021-01-28
   |   
Countries: 
   |   
Clinical Sites: 
Purpose of the study: A strong bidirectional association exists between substance use, various forms of violence and HIV. Substance use accounts for 0.8% of the burden of disease measured in disability adjusted life years (DALYs) among adolescents in South Asia. Violence among adolescents living...

COVID-19 Viral Dynamics

Post Date: 
2020-12-20
   |   
Countries: 
Purpose of the study: This study aims to quantitatively define the relationships between (a) testing results obtained via multiple distinct platforms (antigen vs. RT-qPCR), (b) shedding of infectious virus, and (c) self-reported disease symptoms over the course of SARS-CoV-2 infection.

Impact of Tuberculosis Infection on HIV-1 Antibody Response (NWCS501)

Post Date: 
2020-12-05
   |   
Countries: 
   |   
Clinical Sites: 
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not develop active TB enrolled in ACTG 5274 and ACTG 5279 Study Design: Longitudinal antibody responses will be examined among select participants in A5274 who have plasma samples...

Pharmacokinetic Assessment of MDR-TB Drugs in the Treatment of TB Meningitis

Post Date: 
2020-08-23
   |      |   
Clinical Sites: 
Rationale: MDR-TBM is a devastating disease with high mortality and severe neurologic sequelae among survivors. We recognize the importance of sufficient drug concentrations at the site of infection for efficacy of anti-TB drugs and believe it is likely that drug distribution into brain and CSF...

Identification of Biomarkers That Can Predict Progression from Latent Tuberculosis Infection to Active Tuberculosis Disease

Post Date: 
2020-08-23
   |   
Countries: 
   |   
Clinical Sites: 
Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort (Cohort B). Immunological profiling of TB antigen induced biosignatures, profiling of transcriptional and proteomic biosignatures should provide novel insights into the...

RADx Tech COVID-19 Test US Study

Post Date: 
2020-08-05
   |   
Countries: 
Rationale: Scalable, inexpensive point-of-care (PoC) technologies that enable detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus are desperately needed. However, understanding the accuracy and usability of novel PoC technologies for SARS-CoV-2 is critical. Each PoC...

RADx Tech COVID-19 Test Us Bank

Post Date: 
2020-08-05
   |   
Countries: 
This study is collecting and storing lab samples of COVID-19 diagnostic tests among both people who have tested positive for COVID and those who haven’t to evaluate new COVID test and study how COVID-19 and related viruses cause disease in people.

RADx Tech COVID-19 Test Us Study

Post Date: 
2020-07-27
   |   
Countries: 
Scalable, inexpensive novel technologies that enable detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus are desperately needed. However, understanding the accuracy and usability of novel technologies for SARS-CoV-2 is critical. Each novel test needs to be evaluated...

Epidemiology and Clinical Outcomes of COVID-19 in India (ECO-19)

Post Date: 
2020-07-09
   |   
Countries: 
   |   
Clinical Sites: 
This study was terminated May 25, 2021 This is a prospective cohort study of adults with suspected COVID-19 to address key knowledge gaps in the epidemiology of disease severity and poor clinical outcomes in India. Results from this study may help clinicians in India focus limited health resources...

Tuberculosis (TB) Aftermath

Post Date: 
2020-06-05
   |   
Countries: 
   |   
Clinical Sites: 
Drs. Vidya Mave and Jonathan Golub are co-PIs and Dr. Barthwal from DY Patil Medical College is local site PI for this study. TB Aftermath seeks to provide evidence for an effective and scalable strategy targeting HHs of treated TB cases, a high priority of the NTEP. Purpose To compare the...

Mental Health Outcomes among Health Care Professionals Involved in the Treatment and Care of COVID 19 Patients in India

Post Date: 
2020-06-01
   |   
Countries: 
   |   
Clinical Sites: 
Drs. Nikhil Gupta and Nishi Suryavanshi are leading this survey project. This study is investigating the immediate impact of the COVID-19 pandemic on mental health outcomes and overall quality of life and what are the factors associated with it among Indian Health care workers. Among health care...

Leveraging mHealth and peers to Engage African- Americans and Latinxs in HIV care (LEAN)

Post Date: 
2020-05-12
   |   
Countries: 
Baltimore’s HIV prevalence rate (586/100,000) is among the top 5 in metropolitan areas in the US, and disparities are profound. African Americans have an HIV prevalence that is 5 times higher than among whites, and they account for 78% of all HIV cases. Latinxs also have a higher prevalence of HIV...

Prevalence of Risk Factors for Lung Cancer and Facilitators and Barriers for Tobacco Cessation among People Living with HIV

Post Date: 
2020-04-01
   |   
Countries: 
   |   
Clinical Sites: 
India has the world’s third largest HIV epidemic, with 2.1 million people currently living with HIV and an additional 90,000 new infections each year.[29] At the same time, expansion of the HIV response under India’s premier governmental agency - the National AIDS Control Organization (NACO), has...

Pages

Pages